Advertisement

The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients

  • Author Footnotes
    1 These authors contributed equally to this work.
    Donghua He
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Chunting Zhu
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Xing Guo
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Xin Huang
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Xiaoyan Han
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Gaofeng Zheng
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Yi Zhao
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Yang Yang
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Wenjun Wu
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Jimei Ge
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Enfan Zhang
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Jingsong He
    Correspondence
    Correspondence to: Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, China.
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Zhen Cai
    Correspondence
    Correspondence to: Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, China.
    Affiliations
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
Published:November 25, 2022DOI:https://doi.org/10.1016/j.transci.2022.103618

      Abstract

      Background

      Granulocyte colony-stimulating factor (G-CSF) plus plerixafor has been shown to improve the efficacy of peripheral blood stem cell (PBSC) mobilization, however, due to its high price, the use of plerixafor is limited in China. The purpose of this study was to assess the efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma (MM) patients.

      Materials and methods

      In this single-center retrospective study, 69 MM patients received G-CSF + plerixafor to mobilize PBSCs, which were collected from 28 patients only for one day and 41 patients for two days. Some of the patients received residual plerixafor, and PBSCs were collected on the second day. The data on the characteristics, different doses of plerixafor and efficacy of PBSC mobilization were collected and analyzed.

      Results

      After 1 or 2 apheresis procedures, 85.5% of patients collected more than 2 × 106 cells/kg PBSCs. There was no statistically significant difference in the success rate of CD34 + PBSC mobilization with the different doses of plerixafor on the first day, but the higher residual plerixafor dose resulted in better success rates on the second day (P<0.001). Among the patients who collected PBSCs for two days, the level of the CD34 + cell yield of 24 patients (58.5%) changed better, which was significantly correlated with the dose of residual plerixafor on the second day (P = 0.001).

      Discussion

      These results suggested that the administration of residual plerixafor to mobilize stem cells on the second day is an economical, efficient and clinically feasible method.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mina R.
        • Lonial S.
        Is there still a role for stem cell transplantation in multiple myeloma.
        Cancer. 2019; 125: 2534-2543https://doi.org/10.1002/cncr.32060
        • Al Hamed R.
        • Bazarbachi A.H.
        • Malard F.
        • Harousseau J.L.
        • Mohty M.
        Current status of autologous stem cell transplantation for multiple myeloma.
        Blood Cancer J. 2019; 9: 44https://doi.org/10.1038/s41408-019-0205-9
        • Bueno J.L.
        • Alegre A.
        • Lopez-Villar O.
        • et al.
        Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document.
        Bone Marrow Transpl. 2020; 55: 811-817https://doi.org/10.1038/s41409-019-0716-9
        • Ri M.
        • Matsue K.
        • Sunami K.
        • et al.
        Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
        Int J Hematol. 2017; 106: 562-572https://doi.org/10.1007/s12185-017-2255-8
        • Patterson A.M.
        • Zhang S.
        • Liu L.
        • et al.
        Meloxicam with filgrastim may reduce oxidative stress in hematopoietic progenitor cells during mobilization of autologous peripheral blood stem cells in patients with multiple myeloma.
        Stem Cell Rev Rep. 2021; 17: 2124-2138https://doi.org/10.1007/s12015-021-10259-y
        • Russell N.
        • Douglas K.
        • Ho A.D.
        • et al.
        Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
        Haematologica. 2013; 98: 172-178https://doi.org/10.3324/haematol.2012.071456
        • Fricker S.P.
        Physiology and pharmacology of plerixafor.
        Transfus Med Hemother. 2013; 40: 237-245https://doi.org/10.1159/000354132
        • DiPersio J.F.
        • Stadtmauer E.A.
        • Nademanee A.
        • et al.
        Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
        Blood. 2009; 113: 5720-5726https://doi.org/10.1182/blood-2008-08-174946
      1. Statistics NBo. Resident income and consumption expenditure in 2020. National Bureau of Statistics. 〈http://www.stats.gov.cn/xxgk/sjfb/zxfb2020/202101/t20210118_1812464.html〉; [Accessed 01/08/2021].

        • Kumar S.K.
        • Mikhael J.
        • Laplant B.
        • et al.
        Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
        Bone Marrow Transpl. 2014; 49: 201-205https://doi.org/10.1038/bmt.2013.175
      2. MOZOBIL-plerixafor injection, solution; 2018. 〈https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ed08d2b-5051-46b2-aa37-1d6275bf9003〉.

        • Seki J.T.
        • Bozovic A.
        • Lee R.
        • et al.
        Chemical stability of plerixafor after opening of single-use vial.
        Can J Hosp Pharm. 2017; 70: 270-275https://doi.org/10.4212/cjhp.v70i4.1676
        • Kim S.H.
        • Thiesen J.
        • Krämer I.
        Physicochemical stability of Mozobil® (plerixafor) solution for injection in glass vials and plastic syringes over a three-month storage period.
        Pharm Technol Hosp Pharm. 2016; 1https://doi.org/10.1515/pthp-2016-0011
        • Milone G.
        • Conticello C.
        • Leotta S.
        • et al.
        Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: high effectiveness, low toxicity, and affordable cost.
        Leuk Res Rep. 2020; 14100227https://doi.org/10.1016/j.lrr.2020.100227
        • Choi H.Y.
        • Yong C.S.
        • Yoo B.K.
        Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
        Ann Pharmacother. 2010; 44: 117-126https://doi.org/10.1345/aph.1M380
        • Popat U.
        • Saliba R.
        • Thandi R.
        • et al.
        Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
        Biol Blood Marrow Transpl. 2009; 15: 718-723https://doi.org/10.1016/j.bbmt.2009.02.011
        • Cavallo F.
        • Bringhen S.
        • Milone G.
        • et al.
        Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.
        Leukemia. 2011; 25: 1627-1631https://doi.org/10.1038/leu.2011.131
        • Kumar S.
        • Dispenzieri A.
        • Lacy M.Q.
        • et al.
        Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
        Leukemia. 2007; 21: 2035-2042https://doi.org/10.1038/sj.leu.2404801
        • Lack N.A.
        • Green B.
        • Dale D.C.
        • et al.
        A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.
        Clin Pharmacol Ther. 2005; 77: 427-436https://doi.org/10.1016/j.clpt.2004.12.268
        • Park G.
        • Shayani S.
        • Stiller T.
        • Wang S.
        • Yuan S.
        Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings.
        Transfusion. 2018; 58: 323-329https://doi.org/10.1111/trf.14395
        • Wang J.
        • Tannous B.A.
        • Poznansky M.C.
        • Chen H.
        CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent.
        Pharm Res. 2020; 159105010https://doi.org/10.1016/j.phrs.2020.105010
        • Gutierrez-Aguirre C.H.
        • Alvarado-Navarro D.M.
        • Palomares-Leal A.
        • et al.
        Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
        Transfusion. 2019; 59: 3721-3726https://doi.org/10.1111/trf.15547
        • Dosani T.
        • Covut F.
        • Pinto R.
        • et al.
        Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
        Leuk Lymphoma. 2019; 60: 2199-2206https://doi.org/10.1080/10428194.2019.1573367
        • Li S.
        • Fu J.
        • Ma H.
        • Mapara M.Y.
        • Lentzsch S.
        Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization.
        Leukemia. 2013; 27: 1407-1411https://doi.org/10.1038/leu.2012.323
        • Stewart D.A.
        • Smith C.
        • MacFarland R.
        • Calandra G.
        Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
        Biol Blood Marrow Transpl. 2009; 15: 39-46https://doi.org/10.1016/j.bbmt.2008.10.018
        • Johnsrud A.
        • Ladha A.
        • Muffly L.
        • et al.
        Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +/- plerixafor versus granulocyte colony-stimulating factor +/- plerixafor in the lenalidomide era.
        Transpl Cell Ther. 2021; 27: 590 e1-590 e8https://doi.org/10.1016/j.jtct.2021.04.016
        • Zheng G.
        • He J.
        • Cai Z.
        • et al.
        A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma.
        Oncol Lett. 2020; 19: 1051-1059https://doi.org/10.3892/ol.2019.11177
        • DiPersio J.F.
        • Ho A.D.
        • Hanrahan J.
        • Hsu F.J.
        • Fruehauf S.
        Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting.
        Biol Blood Marrow Transpl. 2011; 17: 943-955https://doi.org/10.1016/j.bbmt.2010.10.018